ArticleInternational neurourology journal2025
Emerging Implantable Tibial Nerve Stimulation Devices for Overactive Bladder.
Article in International neurourology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcutaneous tibial neuromodulation, is the future of neuromodulation here?World journal of urology · 2026Review
- Tibial Nerve Stimulation: Recent Progress and Challenges.Current urology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Overactive bladder (OAB) substantially reduces quality of life (QoL), and novel implantable percutaneous tibial nerve stimulation (iPTNS) devices have emerged as promising alternatives to conventional management. This review provides a comprehensive comparative analysis of iPTNS devices for OAB, evaluating clinical outcomes, technical specifications, regulatory status, innovative features, and limitations-key aspects insufficiently addressed in prior studies. A narrative synthesis was conducted by reviewing clinical trials, technical reports, and regulatory documents related to 7 iPTNS devices. The analysis focused on improvements in health-related QoL (HRQoL), reductions in urgency urinary incontinence (UUI), device design variability, and regulatory distinctions. Our review revealed substantial differences among devices in terms of clinical efficacy (HRQoL and UUI reduction), technical design (including power sources and implantation methods), and regulatory status, with some devices approved by the U.S. Food and Drug Administration and others still under development. While iPTNS devices show considerable promise in OAB management, significant gaps remain regarding long-term outcomes and real-world adherence. Future innovations, particularly closed-loop neuromodulation, hold promise for improving efficacy and advancing personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.